Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Barinthus Biotherapeutics (BRNS) Accumulated Depreciation & Amortization (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 0.78% year-over-year to $5.8 million; the TTM value through Dec 2025 reached $5.8 million, up 0.78%, while the annual FY2025 figure was $5.8 million, 0.78% up from the prior year.
  • Accumulated Depreciation & Amortization hit $5.8 million in Q4 2025 for Barinthus Biotherapeutics, up from $5.8 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $5.8 million in Q4 2025 and bottomed at $886000.0 in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $4.5 million, with a median of $5.4 million recorded in 2023.
  • Year-over-year, Accumulated Depreciation & Amortization surged 387.92% in 2022 and then increased 0.78% in 2025.
  • Barinthus Biotherapeutics' Accumulated Depreciation & Amortization stood at $886000.0 in 2021, then soared by 387.92% to $4.3 million in 2022, then increased by 25.58% to $5.4 million in 2023, then rose by 6.83% to $5.8 million in 2024, then grew by 0.78% to $5.8 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $5.8 million, $5.8 million, and $5.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.